Vol. 7, Issue 2, Part A (2025)

This study explores the transformative role of modern technologies in elucidating the complex interactions between beneficial gut bacteria and intestinal parasites, with a focus on molecular mechanisms and therapeutic innovations. Advanced tools such as CRISPR-Cas9 gene editing, metagenomic sequencing, and AI-driven analytics have enabled precise identification of bacterial strains (e.g., Lactobacillus and Bifidobacterium) that inhibit parasites via resource competition, immune modulation, and secretion of antimicrobial compounds. For instance, engineered Escherichia coli reduced roundworm infections by 60% in animal models, while probiotic interventions in Rwanda lowered schistosomiasis prevalence by 60%. Despite promising outcomes, challenges like microbiome variability and drug resistance persist, necessitating further research for personalized therapies. These advancements highlight the potential of biotechnology and probiotics to combat parasitic diseases affecting over one billion people globally.